文献速递眼底病与葡萄膜炎

阿柏西普治疗初治3型新生血管病变的延长方案疗效与安全性:52周单臂多中心试验

EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial.
PubMed 文献 · Retina · 2020-01-01

这项IV期前瞻性开放标签单臂多中心试验评估阿柏西普2 mg玻璃体腔注射延长方案治疗初治I/II期3型新生血管病变的52周疗效与安全性。32眼纳入,52周最佳矫正视力平均提高10.5个ETDRS字母(P=0.0001),黄斑中心凹和脉络膜厚度分别减少129.1 µm和64.3 µm,视网膜内/下积液比例从87.5%降至11.5%。结论认为该方案可改善视力及视网膜水肿且耐受性良好。

要点

  • 52周最佳矫正视力平均提高10.5个ETDRS字母(P=0.0001),平均注射8.0次。
  • 视网膜内/下积液比例从基线28眼(87.5%)降至52周3眼(11.5%)(P<0.0001)。
  • 7例(21.9%)发生治疗相关不良事件,2例(6.3%)发生严重不良事件。

核心结论

  • 阿柏西普延长方案治疗3型新生血管病变52周可改善视力及视网膜水肿,耐受性良好。

研究设计与样本

  • IV期、前瞻性、开放标签、单臂、多中心试验,纳入初治I/II期3型新生血管病变且基线最佳矫正视力78至23个ETDRS字母的患者。

主要发现

  • 32例患者32眼,平均年龄78.2±7.7岁,女性68.8%,基线最佳矫正视力57.9±15.4(Snellen分数20/70)。
  • 52周最佳矫正视力平均提高10.5±15.9个ETDRS字母(P=0.0001)。
  • 黄斑中心凹厚度平均减少129.1±80.1 µm(P<0.0001),脉络膜厚度平均减少64.3±96.5(P=0.0001)。
  • 视网膜内/下积液比例从基线28眼(87.5%)降至52周3眼(11.5%)(P<0.0001)。
  • 色素上皮脱离和病灶面积52周变化无统计学意义;平均注射次数8.0±2.0次。

关键数值与推荐

  • 7例(21.9%)发生治疗相关不良事件,2例(6.3%)发生严重不良事件。
  • 1例(3.1%)发生需退出治疗的 ocular 严重不良事件(眼内炎),1例(3.1%)发生非眼部自行缓解的严重不良事件(心悸)。
  • 1例(3.1%)发生APTC ATE:非致死性卒中,与试验治疗无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate 52-week efficacy and safety of a treat-and-extend regimen of intravitreal aflibercept 2 mg on treatment-naive Type 3 neovascularization lesions. METHODS: Phase IV, prospective, open-label, single-arm, multicenter trial including patients with untreated Stage I/II Type 3 neovascularization lesions and baseline best-corrected visual acuity between 78 and 23 Early Treatment Diabetic Retinopathy Study letters. Primary endpoint: mean change in best-corrected visual acuity from baseline at 52 weeks. RESULTS: Thirty-two eyes from 32 patients were included (mean ± SD age: 78.2 ± 7.7 years, 68.8% females, baseline best-corrected visual acuity: 57.9 ± 15.4 [Snellen fraction 20/70]). Best-corrected visual acuity increased by 10.5 ± 15.9 Early Treatment Diabetic Retinopathy Study letters at Week 52 (P = 0.0001). The mean foveal and choroidal thickness decreased by 129.1 ± 80.1 µm (P < 0.0001) and 64.3 ± 96.5 (P = 0.0001), respectively. The proportion of patients with intraretinal/subretinal fluid decreased from 28 (87.5%) at baseline to 3 (11.5%) at Week 52 (P < 0.0001). Pigment epithelial detachment and lesion area showed nonsignificant changes over 52 weeks. The mean number of injections was 8.0 ± 2.0. Seven (21.9%) patients experienced treatment-related adverse events and two (6.3%) experienced serious adverse events; one (3.1%) ocular serious adverse event requiring treatment withdrawal, endophthalmitis, and one (3.1%) nonocular spontaneously resolved serious adverse event, palpitations. One (3.1%) patient experienced an APTC ATE: nonfatal stroke not related to trial treatment. CONCLUSION: A treat-and-extend regimen of aflibercept improves visual acuity and retinal edema in eyes with Type 3 neovascularization over 52 weeks with good tolerability.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Arias L, Cervera E, Vilimelis JC, et al. EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial. Retina. 2020. PMID: 31259813. doi:10.1097/IAE.0000000000002582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。